Loading
A phase 3 trial testing HMPL-760 in diffuse large B-cell lymphoma, now recruiting.
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL is a phase 3 interventional study registered as NCT07409428, led by Hutchmed, and recruiting on the registry. Official title: A Phase III Randomised, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Planned enrolment is 240 participants (estimated). The study started in 2026-03-20 and primary completion is expected in 2028-04-30. No results have been posted on ClinicalTrials.gov.